Focus on the development of new drugs in the field of pain.
Provide non-opioid analgesics to satisfy unmet medical needs.
About UsThe Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development.
The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company's product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements.
Delova Biotech focuses on the unmet medical needs in the field of pain in both China and U.S. The Company has laid out nearly 10 new non-opioid analgesics, which have sequen-tially entered the clinical development stage. The Company has also applied for nearly 20 key patents.
We respect the spirit of science, encourage free exploration, focus onclinical needs, and are committed to bringing healthier, more comfortable, and hiqher-level lives to pain patients.
We provide challenging, fulfilling, and fast-growing career opportunitiesand welcome like-minded partners to join!
北京时间2023年09月07日,南京清普生物收到国家药品监督管理局药品审评中心(CDE)关于QP001注射液新药上市申请(NDA)的受理通知书。两个月前,南京清普生物已收到FDA关于QP001项目NDA的正式受理函,NDA号为217593。QP001有望成为国内首款中美同步获批上市的镇痛新药。
【关于QP001】
QP001注射液是清普生物系列非阿片类镇痛新药管线的首款产品,中美双报,可用于治疗各类急性疼痛,尤其适用于术后疼痛,相比现有同类药物在镇痛强度、安全性和镇痛维持时间上均有显著优势。QP001项目基于清普自主知识产权的难溶药物增溶技术平台(SimSolTM)开发。
此前,南京清普生物已收到FDA关于QP001项目的“Application Fee Waivers”(注册费用减免)确认函。根据美国《联邦食品、药品和化妆品法案》(FD&C Act)第736(d)(1)(C)章,南京清普生物可享受QP001项目NDA注册费用部分减免的优惠,成为国内极少数获得FDA“Application Fee Waivers”(注册费用减免)的生物医药公司之一。
本次国内NDA基于两项确证性III期临床试验,共50余家临床研究中心参与,用时9个月不到完成全部受试者入组。两项III期临床结果优异,各主要终点和次要终点均达到统计学差异,确证了QP001注射液在24h内可保持强效镇痛,镇痛强度和安全性均优于同类药物。
QP001项目在近2年时间里接连不断地超预期攻克国内外研发和注册里程碑,完成了多项“国内第一”的壮举,彰显了公司研发团队独一无二的“清普速度”和“清普质量”。
【关于术后疼痛】
术后疼痛是临床上最常见的急性疼痛,通常持续3~7天,创伤大的胸科和关节置换术可持续数周,日间手术离院后需1-2天镇痛。根据《中国卫生健康统计年鉴》报告,2021年我国住院手术达到8103万台,2017-2022年复合增长率(CAGR)约10%,其中约92.6%患者在手术后出现疼痛,48.7%患者术后会经历中度至重度疼痛。
目前我国仍存在术后镇痛不足的现象,我国三级甲等医院有效镇痛率也仅约30%,临床缺少强效且长效的非阿片类镇痛药。术后镇痛不足可使患者处于伤害性应激状态,影响术后恢复,导致住院时间延长,引起睡眠障碍,影响心理情绪和交感神经兴奋,增加心脏负荷影响呼吸功能,使得胃肠蠕动减少和功能恢复延迟等,并有演变为慢性疼痛的风险。
国内外指南共识推荐NSAIDs类药物作为术后多模式镇痛的基础用药,按时给药,并推荐使用长效NSAIDs药物(尤其是日间手术),术前即给予COX-2选择性抑制剂预防性镇痛,进而降低术后阿片类镇痛药的用量,避免阿片类药物成瘾性、呼吸抑制、恶心呕吐、便秘等一系列不良反应。
早秋天气晴好,微风阵阵。为了感谢大家一直以来的付出与努力,公司在9月24日和25日于安吉组织了主题为“To the beyond 走向超越”的秋游活动,让大家从繁忙的工作中得到抽离,亲近自然、舒缓心情。
浙北大峡谷·心跳在云霄
在首日行程中的浙北大峡谷不仅可以体验爬山观水的乐趣,还可以在“云幻之城”高山游乐区进行自我勇气值拉满的高空项目挑战,步步惊心桥、空中自行车、悬崖秋千等多个高空项目激发了小伙伴们挑战自我的勇气,展示真我。
烧烤与篝火·吹动少年的心
日落时分,伴随着烧烤炉中的炭火闪烁,大家开始了2023年秋天的第一场烧烤,刷油、翻面,生疏的动作并不影响烧烤的美味,每出炉一盘肉,就被一扫而空。举杯、摆拍,当下就是最放松且自由的时刻跳动的篝火将轻松愉悦的氛围推向高潮。
竹博园·森呼吸
行程中的第二日是竹博园定向活动,分成三组的小伙伴们,组内齐心协力,组外不甘示弱。
此次秋游,让大家亲近自然,享受美食,不仅得到精神放松,也增进了小伙伴们之间的信任感与情谊一群人,在一起,走向超越,我们未来可期。